Vancomycin-Teixobactin Conjugates

Tech ID: 34185 / UC Case 2025-774-0

Brief Description

A novel approach to significantly enhance vancomycin's effectiveness against drug-resistant pathogens by conjugating it with a minimal teixobactin pharmacophore.

Full Description

This technology involves the conjugation of vancomycin, a critical last-resort antibiotic, with a minimal teixobactin pharmacophore, targeting a different region of lipid II to rescue and enhance its antibiotic activity. This innovative approach has resulted in the creation of conjugates that demonstrate substantial activity improvements against methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible Staphylococcus aureus (MSSA), and even vancomycin-resistant Enterococci (VRE), where both individual components alone were ineffective.

Advantages

  • Significant enhancement in antibiotic activity against Gram-positive bacteria. 
  • Effective against drug-resistant strains such as MRSA and VRE. 
  • Offers a new life to vancomycin by overcoming resistance mechanisms. 
  • Does not require the discovery of new antibiotics, but rather improves existing ones. 
  • Provides a strategic approach to combating antibiotic resistance.

Suggested uses

  • Healthcare industry, particularly in the development of treatments for drug-resistant bacterial infections. 
  • Pharmaceutical companies focused on antibiotic research and development. 
  • Hospitals and clinics dealing with high rates of MRSA, MSSA, and VRE infections. 
  • Public health initiatives aimed at controlling the spread of antibiotic-resistant bacteria.

Patent Status

Patent Pending

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As


5270 California Avenue / Irvine,CA
92697-7700 / Tel: 949.824.2683
  • Facebook
  • Twitter
  • Twitter
  • Twitter
  • Twitter